SLAS Discovery

Papers
(The TQCC of SLAS Discovery is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones152
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery120
Targeting RNA with Small Molecules: Identification of Selective, RNA-Binding Small Molecules Occupying Drug-Like Chemical Space66
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors49
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations49
A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery41
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-238
MALDI-TOF Mass Spectrometry-Based High-Throughput Screening for Inhibitors of the Cytosolic DNA Sensor cGAS38
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response37
Cryo-EM: The Resolution Revolution and Drug Discovery36
Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay33
High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives32
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery32
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids30
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp329
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry29
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity28
Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery25
Identification of Compounds for Butyrylcholinesterase Inhibition25
Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries24
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-1924
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery23
Target Validation Using PROTACs: Applying the Four Pillars Framework23
A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-1922
Target-Directed Approaches for Screening Small Molecules against RNA Targets22
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK221
Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding21
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics20
A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex20
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection20
A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts20
A Framework for Optimizing High-Content Imaging of 3D Models for Drug Discovery19
Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-1919
Application of High-Throughput Automated Patch-Clamp Electrophysiology to Study Voltage-Gated Ion Channel Function in Primary Cortical Cultures18
Using chemical and biological data to predict drug toxicity18
Identification of potent small molecule inhibitors of SARS-CoV-2 entry18
Exploring the Lower Limit of Individual DNA-Encoded Library Molecules in Selection17
Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development17
Applied Biophysical Methods in Fragment-Based Drug Discovery17
Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry16
Evaluating Very Deep Convolutional Neural Networks for Nucleus Segmentation from Brightfield Cell Microscopy Images16
Validating ADME QSAR Models Using Marketed Drugs16
MALDI-TOF-Based Affinity Selection Mass Spectrometry for Automated Screening of Protein–Ligand Interactions at High Throughput16
Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery16
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities16
Lead identification using 3D models of pancreatic cancer16
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry15
Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles15
Comparison of Approaches for Determining Bioactivity Hits from High-Dimensional Profiling Data15
Secretome-Based Screening in Target Discovery15
Z’ Does Not Need to Be > 0.515
ASCT1 and ASCT2: Brother and Sister?15
Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors14
COMPARE Analysis, a Bioinformatic Approach to Accelerate Drug Repurposing against Covid-19 and Other Emerging Epidemics14
In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models14
Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay14
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening14
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets14
Screening Technologies for Inward Rectifier Potassium Channels: Discovery of New Blockers and Activators14
waveRAPID—A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem13
A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids13
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination13
The Problems of Applying Classical Pharmacology Analysis to Modern In Vitro Drug Discovery Assays: Slow Binding Kinetics and High Target Concentration13
Advanced High-Content-Screening Applications of Clonogenicity in Cancer13
Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines13
CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target12
The Impact of Variable Selection Coverage on Detection of Ligands from a DNA-Encoded Library Screen12
Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns12
The Vital Role of Proteomics in Characterizing Novel Protein Degraders12
HighVia—A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity12
Combining Supervised and Unsupervised Machine Learning Methods for Phenotypic Functional Genomics Screening12
Activity-Based Screening Assay for Mono-ADP-Ribosylhydrolases11
Ion Channels and Relevant Drug Screening Approaches11
Optimization of a Colorimetric Assay to Determine Lactate Dehydrogenase B Activity Using Design of Experiments11
A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 Ligands11
Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines11
Luminescence Energy Transfer–Based Screening and Target Engagement Approaches for Chemical Biology and Drug Discovery10
Characterizations of the Urate Transporter, GLUT9, and Its Potent Inhibitors by Patch-Clamp Technique10
Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach10
A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities10
deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids10
Direct Comparison of Label-Free Biosensor Binding Kinetics Obtained on the Biacore 8K and the Carterra LSA10
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication10
Development of a High-Throughput Screening Assay to Identify Inhibitors of the Major M17-Leucyl Aminopeptidase from Trypanosoma cruzi Using RapidFire Mass Spectrometry10
Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1–Nrf2 Protein–Protein Interaction10
Development of a Novel Label-Free and High-Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry10
A High-Throughput Image Cytometry Method for the Formation, Morphometric, and Viability Analysis of Drug-Treated Mammospheres9
Epithelial Barrier Integrity Profiling: Combined Approach Using Cellular Junctional Complex Imaging and Transepithelial Electrical Resistance9
Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening9
Fragment-based screening: A new paradigm for ligand and target discovery9
0.018716096878052